This typically involves periodic blood tests, imaging studies, and fibrosis assessment (using FIB-4 and ELF scores as outlined in NICE NG49) to monitor disease progression
The approval was granted based on demonstrated improvements in MASH and fibrosis, and a confirmatory study is currently underway
Weight loss during menopause is physiologically harder due to declining estrogen and progesterone, which reduces metabolic rate and increases insulin resistance
Incremental Increases: Following the initial phase, the dose is gradually increased every four weeks, under the guidance of your healthcare provider (e.g., to 0.5 mg, then 1.0 mg, and potentially up to 2.4 mg for weight management, as seen with Wegovy, or 2.0 mg for type 2 diabetes, as with Ozempic)
Studies have shown Tirzepatide can lead to even greater long-term weight loss compared to single-pathway medications, making it ideal for patients who need a more powerful metabolic reset
An Austin doctor we spoke with says there are safer, cheaper, and more effective options if you just want to lose weight
